Shin Poong Pharmaceutical (CEO Ryu Jei-Man) had signed an exclusive supply agreement of Medicurtain^® with Greenpine pharmaceutical Co., Ltd. in China on the 7^th of March, 2018. Key agreements are that Shin Poong will exclusively supply Medicurtain^® to Greenpine in China, yet Shin Poong continues to own trademark rights and patents. Total agreement amount is expected to be 10.77 million US dollars for 8 years, with 520 thousand US dollars of loyalty fee.

Medicurtain^®, a surgical adhesion barrier developed by Shin Poong’s own technology, is a combination of hyaluronic acid (HA) with biocompatibilities and wound healing effects, and hydroxyethyl starch (HES) with outstanding anti-blood coagulation and anti-inflammatory action, which is developed uniquely as an anti-adhesion barrier injection for post surgeries.

Large-scale clinical trials have shown that not only the function of forming a physical barrier by highly viscoelastic hyaluronic acid, but also excellent anti-adhesion effect by preventing of thrombosis and inflammation, which is the basis of adhesion. Medicurtain^® satisfies both surgeons and patients by minimizing the adverse events caused by postoperative adhesion and has the equivalent effect of film type prodcuts and convenience of liquid type products. Currently, Medicurtain^® has indications for preventing adhesion formation hysteroscopic, abdominal, spinal, thyroid and nasal/sinus surgeries.